Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Pozycja w akcjach #15446
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Cena akcji
$9.42
Kapitalizacja rynkowa
$354.69M
Zmiana (1 dzień)
-0.83%
Zmiana (1 rok)
91.09%
Kraj
US
Handel BioAge Labs Inc. (BIOA)

Kategoria

Historia stopy dywidendy dla BioAge Labs Inc. (BIOA)
Stopa dywidendy (TTM) dla BioAge Labs Inc. (symbol akcji: BIOA) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla BioAge Labs Inc. (BIOA) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji